News

Enlarge image

ResearchSwitzerland

Turn bad into good fat

28.04.2013 - Swiss scientists have shown for the first time that brown and white fat cells in a living organism can be converted from one cell type to the other.

Using mice as model organisms, the research of the team under Christian Wolfrum from ETH Zurich provides a new approach for anti-obesity therapies. For the first time they demonstrated that energy storing white fat cells can be switched to energy-burning brown fat cells.

For their investigations, Wolfrum et al. made use of the observaton that both humans and mice can adapt to cold temperatures by forming brown fat cells within their white fat depots. These so-called "brite" fat cells (brown-in-white) are less common at warmer than at colder temperatures. To demonstrate whether brite fat cells are formed from white fat cells or other precursors the researchers generated mice with genetically labeled specific fat cells. Exposing them to the cold, the mice formed brite fat cells. After warm adaptation the fat tissue turned white again. The experiments proove that white fat cells can convert into brown fat cells and vice versa. As humans have the same type of cells as mice it is likely that the same process occurs in humans upon cold stimulation.

 The researchers now want to find pharmaceutical or nutritional triggers to convert the cells. According to Wolfrum, this would change the current paradigm of obesity treatment. "Current anti-obesity therapies target the energy intake side of the equation by controlling appetite and the uptake of nutrients", says Wolfrum. The pharmacological treatments that are available are not very efficient and usually are associated with side effects. In contrast, this novel approach to treat obesity would target the energy expenditure side of the equation by promoting brown fat formation. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/turn-bad-into-good-fat.html

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • THERAMETRICS (CH)0.03 CHF50.00%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • EVOCUTIS (UK)0.05 GBP-16.67%
  • BAVARIAN NORDIC (D)33.10 EUR-8.56%
  • SARTORIUS (D)244.55 EUR-6.30%

TOP

  • SYNAIRGEN (UK)35.50 GBP47.9%
  • BIOFRONTERA (D)3.19 EUR36.3%
  • SWEDISH ORPHAN BIOVITRUM (S)15.24 USD27.5%

FLOP

  • EVOCUTIS (UK)0.05 GBP-28.6%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • SERODUS (N)1.48 NOK-24.9%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)29.00 SEK1833.3%
  • NICOX (F)8.59 EUR356.9%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.25 SEK-88.0%
  • BB BIOTECH (D)45.22 EUR-82.7%
  • CYTOS (CH)0.26 CHF-79.5%

No liability assumed, Date: 04.05.2016